

LIST OF TABLES

| Table No. | Table Caption | Pg. No. |
|------------------|---|----------------|
| Table 2-1 | Common signs and symptoms associated with dementia | 15 |
| Table 2-2 | Review of work done on Vinpocetine | 22 |
| Table 2-3 | Review of work done on Noopept | 26 |
| Table 2-4 | Review of work done on transdermal permeation enhancement by chemical and physical means | 28 |
| Table 2-5 | Liposomal and nanoparticulate formulations for transdermal delivery | 31 |
| Table 2-6 | Transdermal delivery through microneedle treated skin | 33 |
| Table 2-7 | Literature on formulation optimization by Response surface design | 36 |
| Table 3-1 | Reported analytical methods for VPN and NPT | 48 |
| Table 3-2 | Formulation prototypes for determination of specificity of analytical methods | 53 |
| Table 3-3 | Absorbance data of VPN in A2M8 and ACN at 0 and 24 h for calibration and stability | 58 |
| Table 3-4 | Sensitivity evaluation of UV methods of VPN in A2M8 and ACN | 59 |
| Table 3-5 | Intraday and interday precision analysis of UV methods using 10 $\mu\text{g/ml}$ standard VPN solutions | 60 |
| Table 3-6 | Accuracy evaluation of UV methods by standard addition technique using 10 $\mu\text{g/ml}$ standard VPN solutions | 60 |
| Table 3-7 | Peak area data of VPN at 0 and 24 h for calibration and stability | 63 |
| Table 3-8 | Sensitivity evaluation of HPLC method of VPN | 64 |
| Table 3-9 | Intraday and interday precision analysis of HPLC methods of VPN | 64 |
| Table 3-10 | Accuracy evaluation of HPLC methods of VPN by standard addition technique | 65 |
| Table 3-11 | Peak area data of NPT at 0 and 24 h for calibration and stability | 67 |
| Table 3-12 | Sensitivity evaluation of HPLC methods of NPT | 68 |
| Table 3-13 | Intraday and interday precision analysis of HPLC methods of NPT | 68 |
| Table 3-14 | Accuracy evaluation of HPLC methods of NPT by standard addition technique | 69 |
| Table 4-1 | Mixture components and their ratio for compatibility evaluation | 77 |
| Table 4-2 | Characteristic FT-IR absorption bands of Vinpocetine in KBr pellet | 78 |
| Table 4-3 | Characteristic FT-IR absorption bands of Noopept in KBr pellet | 80 |
| Table 5A-1 | Quality risk assessment criteria | 87 |
| Table 5A-2 | QTPP elements with justification for VPN loaded UDL | 90 |
| Table 5A-3 | Qualitative risk assessment of independent variables | 92 |

| Table No. | Table Caption | Pg. No. |
|------------------|---|----------------|
| Table 5A-4 | Various material attributes and process parameters along with their levels for screening by fractional factorial design | 94 |
| Table 5A-5 | Randomized batch matrix and resulting CQA for screening design | 94 |
| Table 5A-6 | Various critical material attributes along with their levels for screening by Combined D-optimal design | 96 |
| Table 5A-7 | Randomized design matrix for Combined D-optimal response surface design | 97 |
| Table 5A-8 | Analysis of variance of full as well as reduced quadratic model for vesicular size | 98 |
| Table 5A-9 | Coded coefficients of full as well as reduced quadratic model for vesicle size | 98 |
| Table 5A-10 | Analysis of variance of full as well as reduced quadratic model for drug entrapment | 99 |
| Table 5A-11 | Coded coefficients of full as well as reduced quadratic model for drug entrapment | 99 |
| Table 5A-12 | Summary of full as well as reduced quadratic-linear model for both CQA | 101 |
| Table 5A-13 | Criteria for optimization of VPN UDL | 104 |
| Table 5A-14 | Optimization solution | 107 |
| Table 5A-15 | Results of verification trials | 107 |
| Table 5A-16 | <i>In vitro</i> release profile of VPN from its solution and UDL | 110 |
| Table 5A-17 | Various mathematical models and their correlation coefficient values | 111 |
| Table 5B-1 | Quality risk assessment criteria | 115 |
| Table 5B-2 | QTPP elements with justification for NPT loaded UDL | 118 |
| Table 5B-3 | Qualitative risk assessment of independent variables | 119 |
| Table 5B-4 | Various material attributes and process parameters along with their levels for screening by fractional factorial design | 122 |
| Table 5B-5 | Randomized batch matrix and resulting CQA for screening design | 122 |
| Table 5B-6 | Various critical material attributes along with their levels for screening by Combined D-optimal design | 125 |
| Table 5B-7 | Randomized design matrix for Combined D-optimal response surface design | 125 |
| Table 5B-8 | Analysis of variance of full as well as reduced quadratic model for vesicular size | 126 |
| Table 5B-9 | Coded coefficients of full as well as reduced quadratic model for vesicle size | 127 |
| Table 5B-10 | Analysis of variance of full as well as reduced quadratic model for drug entrapment | 128 |
| Table 5B-11 | Coded coefficients of full as well as reduced quadratic model for drug entrapment | 128 |
| Table 5B-12 | Summary of full as well as reduced quadratic-linear model for both CQA | 130 |

| Table No. | Table Caption | Pg. No. |
|------------------|--|----------------|
| Table 5B-13 | Criteria for optimization of NPT UDL | 134 |
| Table 5B-14 | Optimization solution | 137 |
| Table 5B-15 | Results of verification trials | 137 |
| Table 5B-16 | <i>In vitro</i> release profile of NPT from its solution and UDL | 141 |
| Table 5B-17 | Various mathematical models and their correlation coefficient values | 141 |
| Table 6A-1 | Quality risk assessment criteria | 145 |
| Table 6A-2 | QTPP elements with justification for VPN loaded PNP | 148 |
| Table 6A-3 | Qualitative risk assessment of independent variables | 150 |
| Table 6A-4 | Various material attributes and process parameters along with their levels for screening by fractional factorial design | 152 |
| Table 6A-5 | Randomized batch matrix and resulting CQA for screening design | 152 |
| Table 6A-6 | Various critical material attributes and critical process parameters along with their levels for screening by Box-Behnken design | 156 |
| Table 6A-7 | Randomized design matrix for Box-Behnken response surface design | 156 |
| Table 6A-8 | Analysis of variance of full as well as reduced quadratic model for particle size | 157 |
| Table 6A-9 | Coded coefficients of full as well as reduced quadratic model for particle size | 158 |
| Table 6A-10 | Analysis of variance of full as well as reduced quadratic model for drug entrapment | 159 |
| Table 6A-11 | Coded coefficients of full as well as reduced quadratic model for drug entrapment | 160 |
| Table 6A-12 | Analysis of variance of full as well as reduced quadratic model for drug loading | 161 |
| Table 6A-13 | Coded coefficients of full as well as reduced quadratic model for drug loading | 161 |
| Table 6A-14 | Summary of full as well as reduced quadratic model for all three CQA | 162 |
| Table 6A-15 | Criteria for optimization of VPN PNP | 166 |
| Table 6A-16 | Optimization solution | 168 |
| Table 6A-17 | Results of verification trials | 168 |
| Table 6A-18 | <i>In vitro</i> release profile of VPN from its solution and PNP | 171 |
| Table 6A-19 | Various mathematical models and their correlation coefficient values | 171 |
| Table 6B-1 | Quality risk assessment criteria | 175 |
| Table 6B-2 | QTPP elements with justification for NPT loaded PNP | 178 |
| Table 6B-3 | Qualitative risk assessment of independent variables | 179 |
| Table 6B-4 | Various material attributes and process parameters along with their levels for screening by fractional factorial design | 181 |

| Table No. | Table Caption | Pg. No. |
|------------------|--|----------------|
| Table 6B-5 | Randomized batch matrix and resulting CQA for screening design | 181 |
| Table 6B-6 | Various critical material attributes and critical process parameters along with their levels for screening by Box-Behnken design | 185 |
| Table 6B-7 | Randomized design matrix for Box-Behnken response surface design | 185 |
| Table 6B-8 | Analysis of variance of full as well as reduced quadratic model for particle size | 186 |
| Table 6B-9 | Coded coefficients of full as well as reduced quadratic model for particle size | 187 |
| Table 6B-10 | Analysis of variance of full as well as reduced quadratic model for drug entrapment | 188 |
| Table 6B-11 | Coded coefficients of full as well as reduced quadratic model for drug entrapment | 188 |
| Table 6B-12 | Analysis of variance of full as well as reduced quadratic model for drug loading | 189 |
| Table 6B-13 | Coded coefficients of full as well as reduced quadratic model for drug loading | 190 |
| Table 6B-14 | Summary of full as well as reduced quadratic model for all three CQA | 191 |
| Table 6B-15 | Criteria for optimization of NPT PNP | 195 |
| Table 6B-16 | Optimization solution | 197 |
| Table 6B-17 | Results of verification trials | 197 |
| Table 6B-18 | <i>In vitro</i> release profile of NPT from its solution and PNP | 200 |
| Table 6B-19 | Various mathematical models and their correlation coefficient values | 200 |
| Table 7-1 | Quality risk assessment criteria | 206 |
| Table 7-2 | QTPP elements with justification for fast dissolving MNP | 211 |
| Table 7-3 | Qualitative risk assessment of independent variables | 212 |
| Table 7-4 | Various critical material attributes along with their levels for optimization by Combined D-optimal design | 214 |
| Table 7-5 | Randomized design matrix for Combined D-optimal response surface design | 214 |
| Table 7-6 | Analysis of variance of full quadratic model for axial needle fracture force | 215 |
| Table 7-7 | Coded coefficients of full quadratic model for axial needle fracture force | 216 |
| Table 7-8 | Summary of full quadratic-linear model for ANFF | 216 |
| Table 7-9 | Criteria for optimization of fast dissolving MNP | 219 |
| Table 7-10 | Optimization solution | 220 |
| Table 7-11 | Results of verification trials | 220 |
| Table 7-12 | Pore closure data at different time points | 222 |

| Table No. | Table Caption | Pg. No. |
|------------------|--|----------------|
| Table 7-13 | Total solid content calculation for nanocarriers loaded MNP | 224 |
| Table 7-14 | Axial needle fracture force of various nanocarriers loaded MNP | 225 |
| Table 7-15 | <i>In vitro</i> dissolution profile of various nanocarriers loaded MNP | 226 |
| Table 7-16 | Size and entrapment data of nanocarriers' dispersion initially and after re-dispersion via MNP dissolution | 227 |
| Table 7-17 | <i>In vitro</i> release profile of drug from its nanocarriers loaded MNP | 228 |
| Table 7-18 | Various mathematical models and their correlation coefficient values | 229 |
| Table 8-1 | <i>Ex vivo</i> drug permeation of VPN across full thickness pig ear skin | 237 |
| Table 8-2 | VPN distribution profile after 24 h of permeation experiment | 237 |
| Table 8-3 | <i>Ex vivo</i> drug permeation of NPT across full thickness pig ear skin | 239 |
| Table 8-4 | NPT distribution profile after 24 h of permeation experiment | 239 |
| Table 8-5 | <i>In vitro</i> cell viability data for VPN formulations in HaCaT cell line | 243 |
| Table 8-6 | <i>In vitro</i> cell viability data for NPT formulations in HaCaT cell line | 244 |
| Table 9-1 | Treatment groups for pharmacokinetic study of VPN | 249 |
| Table 9-2 | Treatment groups for pharmacokinetic study of NPT | 250 |
| Table 9-3 | Treatment groups for pharmacodynamic study of VPN | 251 |
| Table 9-4 | Treatment groups for pharmacodynamic study of NPT | 253 |
| Table 9-5 | VPN concentration in plasma at various sampling time points | 253 |
| Table 9-6 | Pharmacokinetic parameters (VPN) computed using Kinetica Software | 254 |
| Table 9-7 | NPT concentration in plasma at various sampling time points | 255 |
| Table 9-8 | Pharmacokinetic parameters (NPT) computed using Kinetica software | 256 |
| Table 9-9 | Mean escape latencies (in second) during training sessions | 257 |
| Table 9-10 | Escape latencies for each treatment group of VPN | 258 |
| Table 9-11 | One way ANOVA results for PD study of VPN | 259 |
| Table 9-12 | Tukey's multiple comparisons test for PD study of VPN | 260 |
| Table 9-13 | Escape latencies for different treatment groups of NPT | 261 |
| Table 9-14 | One way ANOVA results for PD study of NPT | 261 |
| Table 9-15 | Tukey's multiple comparisons test for PD study of NPT | 261 |
| Table 10-1 | Three months' stability data of nanocarriers loaded MNP | 264 |